PTG-300 in Subjects With Hereditary Hemochromatosis
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study will be conducted at multiple sites and every patient will get treated with
PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult
hereditary hemochromatosis patients.
Phase:
Phase 2
Details
Lead Sponsor:
Protagonist Therapeutics Protagonist Therapeutics, Inc.